2011 ASH Program Book - American Society of Hypertension
2011 ASH Program Book - American Society of Hypertension
2011 ASH Program Book - American Society of Hypertension
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Sunday Morning MAY 22<br />
Posters<br />
PO-163: Effect <strong>of</strong> Aliskiren and Antihypertensive Drugs on<br />
Diastolic Function in Hypertensives with Diastolic<br />
Dysfunction: A Randomised Study<br />
Maria Leonarda De Rosa. University <strong>of</strong> Naples<br />
Federico II, Naples, IT.<br />
PO-164: Effects <strong>of</strong> Add-On Nebivolol on Blood Pressure and<br />
Glucose Parameters in Hypertensive Patients with<br />
Prediabetes<br />
P. Deedwania†, 1 D. G. Cheung, 2 J. Shea, 3 W. Chen, 3 J. J.<br />
Whalen. 3 1 UCSF, US; 2 Long Beach Center for Clinical<br />
Research, US; 3 Forest Research Institute, US.<br />
PO-165: Incident Diabetes with Antihypertensive Drugs:<br />
Updated Network and Bayesian Meta-Analyses <strong>of</strong><br />
Clinical Trial Data<br />
William J. Elliott†, 1 Sanjib Basu, 2 Peter M. Meyer. 2<br />
1 Pacific Northwest University <strong>of</strong> Health Sciences,<br />
Yakima, WA, US; 2 RUSH Medical College, Chicago,<br />
IL, US.<br />
PO-166: Efficacy and Safety <strong>of</strong> Combination DRI/CCB (±<br />
Diuretic) in US Minority Patients with Stage 2<br />
<strong>Hypertension</strong> and Obesity<br />
Keith C. Ferdinand†, 1 Richard Weitzman, 2 Das<br />
Purkayastha, 2 Kanaka Sridharan, 2 Edgar A. Jaimes. 3<br />
1 Emory University, Atlanta, GA, US; 2 Novartis<br />
Pharmaceuticals Corporation, East Hanover, NJ,<br />
US; 3 The University <strong>of</strong> Alabama at Birmingham,<br />
Birmingham, AL, US.<br />
PO-167: Efficacy <strong>of</strong> Combination Aliskiren/Amlodipine with<br />
and without Diuretic on Ambulatory Blood Pressure<br />
in Minorities with <strong>Hypertension</strong><br />
Keith C. Ferdinand†, 1 Richard Weitzman, 2 Das<br />
Purkayastha, 2 Kanaka Sridharan, 2 Edgar A. Jaimes. 3<br />
1 Emory University, Atlanta, GA, US; 2 Novartis<br />
Pharmaceuticals Corp, East Hanover, NJ, US; 3 The<br />
University <strong>of</strong> Alabama at Birmingham, Birmingham,<br />
AL, US.<br />
PO-168: Role <strong>of</strong> Plasma Renin Activity on BP Response to<br />
Aliskiren-Based Therapy in Stage 2 Hypertensive<br />
African <strong>American</strong>s<br />
Keith C. Ferdinand†, 1 Richard Weitzman, 2 Das<br />
Purkayastha, 2 Kanaka Sridharan, 2 Edgar A. Jaimes. 3<br />
1 Emory University, Atlanta, GA, US; 2 Novartis<br />
Pharmaceuticals Corporation, East Hanover, NJ,<br />
US; 3 The University <strong>of</strong> Alabama at Birmingham,<br />
Birmingham, AL, US.<br />
PO-169: Efficacy and Safety <strong>of</strong> Combination DRI/CCB<br />
(±Diuretic) Therapy in African <strong>American</strong>s with<br />
Stage 2 <strong>Hypertension</strong><br />
Keith C. Ferdinand†, 1 Richard Weitzman, 2 Das<br />
Purkayastha, 2 Kanaka Sridharan, 2 Edgar A. Jaimes. 3<br />
1 Emory University, Atlanta, GA, US; 2 Novartis<br />
Pharmaceuticals Corporation, East Hanover, NJ,<br />
US; 3 The University <strong>of</strong> Alabama at Birmingham,<br />
Birmingham, AL, US.<br />
113
Change language